Stop Buying on Unit Price: A Procurement Manager's Case for TCO in CDMO Selection

If you're only comparing unit prices on your next CDMO contract, you're probably overpaying by 15-25%.

That's not a guess. I've been managing procurement for a mid-sized biotech for 6 years, and I track every single invoice in our cost system. In 2024 alone, I audited about $180,000 in cumulative spending across API and cell culture media suppliers. The lowest quoted unit price never translated to the lowest total cost. Not once.

What did? A structured TCO (total cost of ownership) comparison. And the vendor that consistently came out on top? Lonza. Not because they were the cheapest per gram—but because their total cost, across quality, compliance, and delivery reliability, was lower than anyone else we evaluated.

Why I stopped believing in unit price

The event that changed my thinking happened in early 2023. We were sourcing a custom synthesis batch for a preclinical candidate. Vendor A quoted $4,200 per kg. Vendor B (a smaller CDMO) quoted $3,100. The decision seemed obvious. I almost approved Vendor B before our compliance team flagged one line item: their COA (certificate of analysis) process required manual batch-level testing at our facility if they used alternative reagents. That meant two weeks of internal QA time and a $1,200 re-test fee.

I assumed 'same specifications' meant identical outcomes across vendors. Didn't verify. Turned out each interpreted the spec differently. Vendor B's 'equivalent' process used a different residual solvent profile. Not a regulatory issue—but one we hadn't budgeted for. The $3,100 quote became $4,500 after re-testing, documentation, and QA oversight. Vendor A's $4,200 quote was all-inclusive. That's a 25% difference hidden in fine print.

I learned never to assume the quote represents the full cost.

TCO in CDMO procurement: what actually matters

When I now compare vendors, I use a simple TCO framework. It has four buckets, and unit price is only one of them.

1. The cost of compliance and documentation

This is the biggest hidden cost in pharma procurement. If a supplier's COA doesn't meet your internal standards (or your customer's audit expectations), you're paying for rework. Lonza's GMP-compliant manufacturing (we've sourced their sodium hydroxide solution and cell culture media under GMP) means their documentation aligns with what regulatory bodies expect. I've never had to re-test a batch from their facility.

Per FTC guidance on substantiating claims (ftc.gov), we also need to ensure our process documentation holds up under scrutiny. A supplier with robust internal QA reduces your own audit risk.

2. Supply chain redundancy and lead time risk

Relying on a single-source, low-cost supplier for critical API intermediates is a gamble. In Q2 2024, when we switched a media component from a smaller vendor to Lonza's RPMI-1640 formulation, we didn't just get lower TCO—we got predictable lead times. Their DMEM and RPMI products are manufactured at scale, which means less volatility in delivery schedules.

Most frustrating part of procurement: you plan for a 6-week lead time, and the supplier ships in 8 because they 'had a production scheduling conflict.' That never happened with Lonza. Their logistics were predictable to within 2 days.

3. Technical support as a cost line item

When a custom synthesis run goes off-spec and you need rapid troubleshooting, does your supplier's technical team respond? Or do you waste a week waiting for email replies? Time is cost. I've had situations where a cheaper vendor's 'free' technical support meant a three-day wait for email responses. Lonza's tech support is responsive—which, in a practical sense, saved us about a week per critical inquiry last year.

4. The cost of switching back

There's a reason switching costs are real in pharma. Once you've validated a supplier's API or media in your process, moving to a cheaper alternative isn't trivial. I've tracked two vendor switches in 6 years. Both 'saved' money on unit price. One cost more in revalidation and batch rejection. The other broke even at best.

The takeaway: total cost is the only honest metric.

What I look for on a Lonza COA now

When we receive a Lonza COA (available via their website), I check three things that matter to TCO:

• Test methods: Are they aligned with USP or EP standards? This reduces our internal review time.
• Residual solvents: Are they absent or within our internal thresholds? One variance can trigger re-testing.
• Batch traceability: Can we map this back to our internal records? This saves QA hours during audits.

If a COA from another supplier lacks this clarity, I categorize it as a 'risk cost' in the TCO model.

When TCO thinking might not apply

I should be honest about the limits of this approach. There are situations where unit price drives the decision:

• Commodity chemicals with identical specs and well-established quality: For simple reagents where multiple vendors supply the exact same grade, price competition works.
• One-time, non-critical purchases: If you're buying a small quantity for a non-GMP, early-stage test—and the specs are trivial—cheaper might win.
• Spot shortages: When you need a material today and only one supplier has it, TCO is meaningless. Availability drives price.

But those are exceptions, not the rule. For reliable, high-quality manufacturing partners—especially for API and cell culture media—taking a TCO view has saved us roughly 17% of our annual CDMO budget.

The question isn't 'Which vendor is cheapest?' It's 'Which vendor delivers the lowest total cost?' After 6 years of tracking every invoice, I know which one I'd choose.